Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025
Advanced Therapeutic Strategies and Resistance Mechanisms in CLL
Shankara Paneesha, MD FRCP FRCPath
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
MET and Other Emerging Targets in Metastatic NSCLC
HER2-Driven Strategies in Metastatic NSCLC
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Sapna Patel, MD
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD
Applications of Emerging Data in Resectable NSCLC
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.